Eli Lilly’s Taltz beats Novartis to the punch with FDA approval in spondyloarthritis – FiercePharma
Eli Lilly’s Taltz and Novartis’ Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come […]
